<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03528577</url>
  </required_header>
  <id_info>
    <org_study_id>CLR_17_08</org_study_id>
    <nct_id>NCT03528577</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)</brief_title>
  <official_title>A Randomized, Single-Dose, Double-Blind, Double-Dummy, Four-Period, Four-Sequence, Four-Treatment, Placebo and Active Controlled, Comparative, Multiple-Center, Crossover-Design, Bronchoprovocation Study to Evaluate the Pharmacodynamic Equivalence of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited) to PROAIR® HFA (Albuterol Sulfate) Inhalation Aerosol, eq 90 mcg Base (Teva Respiratory, LLC) in Subjects With Stable, Mild Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharmaceutical Industries Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharmaceutical Industries Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Evaluate the Pharmacodynamic Equivalence of Albuterol Sulfate Inhalation Aerosol, eq 90
      mcg base (Sun Pharmaceuticals Industries Limited) to PROAIR® HFA (albuterol sulfate)
      Inhalation Aerosol, eq 90 mcg base (Teva Respiratory, LLC) in Subjects With Stable, Mild
      Asthma
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">January 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacodynamic endpoint post-dose PC20</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">123</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Albuterol Sulfate Inhalation Aerosol, eq 90 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PROAIR® HFA (albuterol sulfate) Inhalation Aerosol, eq 90 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for Albuterol Sulfate Inhalation Aerosol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for Albuterol Sulfate Inhalation Aerosol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zero-dose</intervention_name>
    <description>Treatment A</description>
    <arm_group_label>Test</arm_group_label>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_label>Test Placebo</arm_group_label>
    <arm_group_label>Reference Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>90 mcg of PROAIR® HFA</intervention_name>
    <description>Treatment B</description>
    <arm_group_label>Test</arm_group_label>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_label>Test Placebo</arm_group_label>
    <arm_group_label>Reference Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>180 mcg of 90 mcg of PROAIR® HFA</intervention_name>
    <description>Treatment C</description>
    <arm_group_label>Test</arm_group_label>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_label>Test Placebo</arm_group_label>
    <arm_group_label>Reference Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>90 mcg of albuterol sulfate inhalation aerosol</intervention_name>
    <description>Treatment D</description>
    <arm_group_label>Test</arm_group_label>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_label>Test Placebo</arm_group_label>
    <arm_group_label>Reference Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or non-pregnant women 18 to 65 years of age.

          2. Signed informed consent form that meets all criteria of current Food and Drug
             Administration (FDA) regulations.

          3. Females of childbearing potential must not be pregnant or lactating (as confirmed by a
             negative urine pregnancy test

          4. Ability to use inhalation aerosol correctly.

        Exclusion Criteria:

          1. Any clinically significant finding on physical exam in the opinion of the
             Investigator, would compromise subject's safety or data integrity.

          2. Employees of the Investigator or research center or their immediate family members.

          3. Previous participation in this study.

          4. Inability to understand the requirements of the study and the relative information and
             are unable or not willing to comply with the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shravanti Bhowmik, MD</last_name>
    <phone>912266455645</phone>
    <email>shravanti.bhowmik@sparcmail.com, mudgal.kothekar@sparcmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SPARC Site 02</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manuel Hernandez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SPARC site 01</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gordon Raphael</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SPARC SIte 04</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philip Korenblat</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SPARC Site 07</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Selwyn Spangenthal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SPARC Site 06</name>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <zip>28054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anup Banerjee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SPARC Site 05</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeremy Cole</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SPARC Site 03</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Niran Amar</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2018</study_first_submitted>
  <study_first_submitted_qc>May 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2018</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Procaterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

